TR1X
Tr1x develops cellular therapies intended for the treatment of autoimmune disorders. The company utilizes its exclusive platform to produce cutting-edge cell therapy products designed to recalibrate the immune system and reinstate homeostasis, ultimately fostering long-term tolerance.
TR1X
Social Links:
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2018-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.tr1x.bio
Total Employee:
11+
Status:
Active
Total Funding:
75 M USD
Technology used in webpage:
CrUX Dataset CrUX Top 50m
Similar Organizations
Allumeros BioScience
Allumeros BioScience develops and researches on therapeutic and diagnostic advancements for treatment of cancer cells.
Auctus Surgical
Auctus Surgical is developing a dynamic Vertebral Body tethering system for the treatment of pediatric scoliosis.
Cell Receptor
Cell Receptor develops a future-oriented therapy for high medical needs: cancer and autoimmune diseases
Pediatric Bioscience
Pediatric Bioscience develops products to improve the diagnosis and treatment of children with autism and autism spectrum disorders.
SetPoint Medical
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
Stem Cell Medicine
Stem Cell Medicine is a developer of cellular therapies in tissue repair and for the treatment of inflammatory disorders.
Tachyon Therapeutics
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Investors List
The Column Group
The Column Group investment in Series A - Tr1x
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Tr1x
Neva SGR
Neva SGR investment in Series A - Tr1x
Neva SGR
Neva SGR investment in Series A - Tr1x
Official Site Inspections
http://www.tr1x.bio
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Tr1x"
About Us | Tr1x
Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at …See details»
Tr1x 2025 Company Profile: Valuation, Funding
Tr1x General Information Description. Developer of cell therapies intended for the treatment of autoimmune disorders. The company advances in genetic …See details»
Tr1x - Crunchbase Company Profile & Funding
Tr1x may be growing as it has recently unveiled a significant funding round of $75 million, which is indicative of investor confidence and provides capital for …See details»
Tr1X - LinkedIn
Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.See details»
Science | Tr1x
Tr1X was established to translate key academic discoveries in T-regulatory type 1 (Tr1) cell function and biology into commercially available treatments. 2009. Tr1 Cells . Tr1 Cells are found in patients with tolerance following allogeneic stem …See details»
Tr1X - Company Profile - Tracxn
Jan 28, 2025 Tr1X doses first patient in trial of TRX103 for GvHD preventionClinical Trials Arena • Jul 11, 2024 • Tr1X Tr1X Announces FDA Clearance of First Investigational New Drug …See details»
Tr1X Announces FDA Clearance of First Investigational …
Apr 10, 2024 For more information visit www.tr1x.bio. Investor Contact: Tr1X Investor Relations [email protected] Media Contact: Julie Normart [email protected] SOURCE Tr1X, Inc.See details»
Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise
Jan 17, 2024 Biotechnology company Tr1x on Wednesday became the latest startup to raise tens of millions of dollars in venture funding to develop a new type of cell therapy for …See details»
Tr1X - BioSpace
Jan 18, 2024 Tr1X is a private, clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory …See details»
Tr1X, Inc. Announces $75 Million Series A Financing to ... - BioSpace
Jan 17, 2024 About Tr1X Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, …See details»
Tr1X - VentureRadar
Website: https://www.tr1x.bio. Advances cell therapy via innovative research and development, fostering a collaborative and diverse environment to revolutionize medical treatments and …See details»
Tr1X, Inc. Announces $75 Million Series A Financing to Develop …
Jan 17, 2024 For more information visit: www.tr1x.bio. Investor Contact: Tr1X Investor Relations [email protected] Media Contact: Julie Normart [email protected] SOURCE Tr1X, Inc.See details»
Tr1X to Participate at Upcoming Healthcare Investment
Sep 13, 2024 To attend the aforementioned conferences and/or meet management at Tr1X please reach out to your institutional representative at each organization.See details»
Tr1x - Contacts, Employees, Board Members, Advisors & Alumni
Tr1x develops universal cellular therapies intended for the treatment of autoimmune disorders.See details»
Our Programs | Tr1x
Severe refractory Inflammatory Bowel Disease (IBD) is a persistent, acute, symptomatic gut disease that continues to significantly impact the quality of life of patients despite continued …See details»
Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A
Jan 18, 2024 Pictured: Cell therapy concept/iStock, Meletios Verras. Tr1X came out of stealth mode on Wednesday with $75 million in Series A funding as it looks to bring allogeneic …See details»
Tr1X Announces Succession Plan: Appoints David de ... - Markets …
1 day ago Tr1X is a clinical-stage private biotechnology company pioneering a new class of curative cell therapies designed to fundamentally reset the immune system in patients with …See details»
Tr1x | biotechnology company, Treg cell therapies, Zoonop
Tr1X was founded to address unmet medical needs in the field of autoimmune diseases by leveraging breakthrough cell therapy technologies. With foundational work led by Dr. Maria …See details»
BIOTECH (140) Tr1X: T Regulatory Type 1 (Tr1) Cell Therapy for ...
Mar 18, 2024 Tr1X Bio “Our VC investors are confident in our world-class team’s ability to revolutionize the field through our innovative, breakthrough science,” David de Vries, MPhil, …See details»
BIO Statement on Resignation of Peter Marks from the FDA
1 day ago John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the …See details»